Drug Profile
TT 173
Alternative Names: TT-103; TT-103MH; TT-173; Yeast-derived microvesicles containing recombinant Tissue FactorLatest Information Update: 17 Aug 2022
Price :
$50
*
At a glance
- Originator Thrombotargets Corporation
- Class Antihaemorrhagics; Recombinant proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Blood coagulation disorders
Most Recent Events
- 17 Aug 2022 Protheragen has patents pending for TT 173 before August 2022 (Protheragen website, August 2022)
- 27 Sep 2021 TT 173 is still in phase II/III trials for Blood coagulation disorders in Spain (Topical, Powder) (EudraCT2015-003408-21)
- 11 Oct 2007 TT 173 receives Orphan Drug status for Von Willebrand's disease in USA